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The aim of this study is to characterize the factors related to peptidoglycan metabolism in isogenic hVISA/
VISA ST100 strains. Recently, we reported the increase in IS256 transposition in invasive hVISA ST100
clinical strains isolated from the same patient (D1 and D2) before and after vancomycin treatment and two
laboratory VISA mutants (D23C9 and D2P11) selected from D2 in independent experiments. High performance
liquid chromatography-mass spectrometry (HPLC-MS) analysis of peptidoglycan muropeptides showed increased
proportion of monomeric muropeptides and a concomitant decrease in the proportion of tetrameric muropeptide in
D2 and derived mutants when compared to the original strain D1. In addition, strain D2 and its derived mutants
showed an increase in cell wall thickness with increased pbp2 gene expression. The VISA phenotype was not
stable in D2P11 and showed a reduced autolysis profile. On the other hand, the mutant D23C9 differentiates from
D2 and D2P11 in the autolysis profile, and pbp4 transcription profile. D2-derived mutants exhibited differences in
the susceptibility to other antimicrobials. Our results highlight the possibility of selection of different VISA
phenotypes from a single hVISA-ST100 genetic background.
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Background
Staphylococcus aureus is an important opportunisticpathogen that has the ability to acquire resistance to a great
number of antimicrobial agents. Currently, the main concern
comes from methicillin-resistant S. aureus (MRSA), which
generally harbor additional antibiotic resistance determinants.
Vancomycin (VAN) is themain alternative for the treatment
of severe infections caused byMRSA, but from the late 90s, the
increase in reports of vancomycin-intermediate S. aureus
(VISA) and heterogeneous vancomycin-intermediate S. aureus
(hVISA) has raised an alarm worldwide.1,2 Subsequently, in-
creased reports of vancomycin failure started to appear and
the efficacy of vancomycin in the treatment of many serious
infections has been questioned.
To date, the underlying mechanism responsible for the
hVISA/VISA phenotype is not yet fully understood. A thick-
ened cell wall is a common feature described among most
VISA isolates reported, possibly preventing vancomycin
diffusion to its target in the division septum where peptido-
glycan synthesis occurs. Notwithstanding, there is a large
number of phenotypic and genotypic features associated with
the resistance, and it has been proposed that VISA strains
emerge by mutations from vancomycin-susceptible S. aureus
by a step-wise process with hVISA as intermediary.3
Some hVISA/VISA strains were described to have ab-
normal growth rate, increased concentration of free D-Ala-D-
Ala terminal peptidoglycan precursors, and reduced cell wall
turnover and autolytic rates.2 It has been observed that after
incubation in a drug-free medium or prolonged storage, re-
sistance phenotype can revert to a more susceptible one.2,4 In
addition, it has been described that the loss of functionality of
the agr locus may confer an adaptive advantage under van-
comycin selective pressure.5
Point mutations in regulatory genes such as vraSR, graSR,
walKR, rpoB, and cmk6–10 were associated to VAN resistance.
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Furthermore, disruption of genes involved in cell wall syn-
thesis (tca, walKR), by IS256 insertions, led to VISA phe-
notype.11–13
Recently, we reported the increase in IS256 transposition
in an invasive hVISA ST100 clinical isolate and its derived
VISA mutants.14 The aim of this study is to characterize the
factors related to peptidoglycan metabolism in these iso-
genic ST100 strains.
Materials and Methods
Strains and culture conditions
S. aureus strains D1 and D2 were isolated from a patient
suffering bone and joint infection, before and after 40 days
of vancomycin treatment. Detailed clinical history of the
patient was recently described.14 In vitro selection of D2-
derived mutants (D23C9, D2P11) was performed in two
independent experiments by serial passage with increasing
concentrations of vancomycin (Sigma-Aldrich). All strains
were grown on the BHI (Britania, Argentina) broth at 37C
with aeration. Mutant D23C9 and D2P11 were selected at 9
and 11mg/ml of vancomycin, respectively.14 Relevant
properties of these strains are listed in Table 1.
Susceptibility testing
Stability of vancomycin resistance was assayed by deter-
mining the MIC (microdilution method) according to CLSI
guidelines in three independent experiments for D2 and its
derived mutants after 30 and 60 days of serial passage in
BHI agar without antibiotic. Daptomycin susceptibility was
analyzed by prediffusion method (Neosensitabs; Rosco
Diagnostica) and Etest (AB BioMerieux, Solna, Sweden)
according to the manufacturer’s instructions.
Transmission electron microscopy
Strains were grown in the BHI broth, until they reached an
OD620nm= 0.5–0.7. Preparation and examination of S. aureus
cells by transmission electron microscopy (TEM) were
performed as described previously.15 Ultrathin sections
of the samples were examined using a Zeiss 10C elec-
tron microscope and images analyzed with Image J 1.46r
software (http://imagej.nih.gov/ij/). Cell wall thickness
at nearly equatorially cut surfaces was measured (30 cells
for each strain) using a magnification of 50,000 · , and
the results for each strain were expressed as median
and range.
Characterization of the peptidoglycan
Peptidoglycan was isolated as previously described16 and
digested with mutanolysin (Sigma-Aldrich). Reaction mixture
was incubated overnight at 37C, and the solublemuropeptides
were separated by reversed phase-high performance liquid
Chromatography using a 3mm ODS-Hypersil column (4.6–
250mm; Thermo Scientific), at 25C. The compounds were
detected at 210 nm. HPLC elution patterns are included in
Supplementary Data 1; (Supplementary Data are available
online at www.liebertpub.com/mdr) The areas of the peaks
were added together, and individual peaks were expressed as a
percentage of the total.
Relevant peaks were collected and lyophilized. Samples
were hydrolyzed in 6M HCl at 95C for 16hr. After evap-
oration, the dry residues were dissolved in 67mM trisodium
citrate-HCl (pH= 2.20) and injected into a Hitachi L8800
analyzer equipped with a 2620MSC-PS column (Science-
Tec). The structure and purity of isolated PG fragments were
confirmed by MALDI-TOF mass spectrometry (MS) on a
PerSeptive Voyager-DE STR instrument (Applied Biosys-
tems) equipped with a 337 nm laser.
Membrane purification and Penicillin Binding
Proteins analysis
Membrane fractions were prepared by ultracentrifugation
from cultures in the exponential phase as previously de-
scribed.17,18 One hundred micrograms of membrane fraction
was incubated with 25mMof fluorescent ampicillin for 30min
to detect all PBPs.17 The labeling of PBP2Awas performed by
adding 200mMampicillin for 10min at 37Cbefore incubation
with the fluorescent antibiotic. Proteins were separated by 10%
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE), and then visualized with a fluorescence scanner
(Molecular Imager FX PhosphoImager; BioRad).
Autolysis assay
Strains were grown in the BHI broth until they reached an
OD620nm = 0.5–0.7, chilled on ice, harvested by centrifuga-
tion (3,000 g, for 10min at 4C), and washed with ice-cold
water. Cells were then suspended to an OD620nm = 1.0 either
in the lysis buffer (50mM glycine buffer, pH = 8.00, con-
taining 0.01% Triton X-100) as previously described19 or
in 50mM phosphate buffer, pH = 7.00, and incubated at
37C with agitation. Autolysis was evaluated by following
OD620nm.
Table 1. Relevant Characteristics of the Bacterial Strains Used in This Study
D1 D2 D23C9 D2P11 Reference
MIC (mg/ml)
VAN 0.5 1 4 8 15
RIF 8 4 1 2 15
DAP 0.094 0.38 0.5 1 This study
DAP predifussion method (mm) 30 30 22 18 This study
VAN PAP-AUC/PAP-AUC Mu3 0.98 1.48 2.81 5.7 15
Phenotype hVISA hVISA VISA VISA 15
Cell wall thickness (nm)
(median; range)
26.20;
23.57–28.74
33.41;
27.17–39.42
34.07;
27.23–45.15
35.54;
27.75–49.49
This study
DAP, daptomycin; hVISA, heterogeneous vancomycin-intermediate Staphylococcus aureus; RIF, rifampin; VAN, vancomycin.
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PBP2 and PBP4 transcription analysis by RTqPCR
The transcription of PBP2 and PBP4 coding genes
was evaluated by reverse transcription quantitative real-time
polymerase chain reaction (RTqPCR) using primers de-
scribed in Supplementary Data 2. The effect of vancomycin
at subinhibitory concentration (¼ MIC) on the pbp2 and pbp4
transcription was further analyzed. RNA was isolated by trip-
licate, in three independent experiments, from bacteria grown
in the BHI broth, in the presence of VAN (¼MIC) or without
antibiotic, until they reached an OD620nm= 0.5–0.7. Cells were
collected by centrifugation and bacterial pellets were treated
with lysozyme 15mg/ml (Sigma-Aldrich) in 10mM Tris-HCl
(pH= 8.00), 0.1mM EDTA, for 1 hr at 37C and RNA was
extracted using TRIZOL Reagent (Invitrogen) with the Pure
LinkRNAMini Kit (AMBION) according to manufacturer’s
recommendations. RNA was quantified using NanoDrop
1000 spectrophotometer (Thermo Scientific) and treated with
3U/ml DNAse for 1 hr at 37C (RQ1 RNase free DNase; Pro-
mega). Reverse transcription was performed using 500 ng of
RNA, 200U ofM-MLVReverse Transcriptase (Invitrogen),
and 50mM Random primers (Invitrogen) according to manu-
facturer’s recommendations. The qPCR reaction was carried
out using a 1/100 dilution of cDNA, SYBRSelectMasterMix
(Applied Biosystems) and the primers previously described in
a 7500 Real-Time PCR System (Applied Biosystems).
The combination of gyrB and pta was used as reference
genes. Cq values were converted into normalized relative
quantity (NRQ) values using normalization to the geomet-
rical average of the reference genes and the specific PCR
efficiency for each gene.20–23
Statistical analysis
The NRQ values of pbp2 and pbp4 genes were converted
into logarithmic values to obtain symmetrical data and
compared by two-way analysis of variance (ANOVA).
Multiple comparisons were performed with the Duncan
post-test using Infostat Software.24 p Values of <0.05 were
considered statistically significant.
Cell wall thickness values were compared with the non-
parametrical Kruskal–Wallis test and Dunn post-test using
Infostat Software. p Values of <0.05 were considered sta-
tistically significant.
Sequencing of candidate loci involved
in VAN resistance
The complete vraTSR operon, walKR operon, graXRS
operon, and the RRDR region of the rpoB gene were am-
plified by PCR.7,11,25–28 Purified amplicons were sequenced
and compared with the S. aureus N315 genome sequence
(NCBI Reference Sequence: NC_002745.2).
Results
Previously, we reported that strains isolated from the same
patient (D1 and D2) and the laboratory-selected mutants
(D23C9 andD2P11) displayed distinct antibiotic susceptibility
FIG. 1. HPLC muropeptide profile analysis. Area under
curve of relevant peaks (expressed as percentage of the total
area), and proposed structures for muropeptides corresponding
to peaks: (A) eluted at RT 47 min and (B) eluted at RT 64 min,
after MS amino acid analysis. HPLC, high performance liquid
chromatography; MS, mass spectrometry; RT, retention time.
FIG. 2. Autolysis assay performed using (A) 50mM
phosphate buffer pH = 7.00 and (B) lysis buffer (0.01%
Triton X-100, 5mM glycine pH = 8.00). Data were ex-
pressed as the percent loss of OD620nm at the indicated
times compared to the zero time point. Each data point
represents the mean and standard deviation from three
independent experiments.
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patterns (Table 1). Daptomycin susceptibility was additionally
explored in this study. Daptomycin prediffusion method was
positive for D2P11, suggesting the potential reduction in
daptomycin susceptibility for this strain. Daptomycin MIC
values were higher for the derived mutants D2P11 and D23C9
compared to the parental strain, but all of them are classified as
susceptible according to CLSI breakpoint (Table 1).
The stability of the hVISA/VISA phenotype was explored
by the determination of vancomycinMIC after daily passages
in the drug-free medium. While vancomycin MIC value re-
mained unchanged in D2 and D23C9 mutant, the MIC of
mutant D2P11 decreased twice (to 2 mg/ml) after 60 daily
passages in the drug-free medium, suggesting some insta-
bility in its phenotype.
We compared D1 cell wall thickness with its derived
mutants: the observed values were significantly different
( p < 0.0001, Kruskal–Wallis). Increased cell wall thickness
was detected by TEM in D2 and its derived mutants when
compared to the D1 strain ( p < 0.05, Dunn) (Table 1).
Purified peptidoglycan was prepared from the four strains,
digested with M1 muramidase, and analyzed by reversed-
phase HPLC. The muropeptide composition of D2, D23C9,
and D2P11 showed an increased proportion in pentaglycine
-disaccharide pentapeptide monomer together with a de-
creased proportion of the tetramer muropeptide when
chromatograms were compared to D1 (Fig. 1). The differ-
ence was major in D23C9 mutant (Fig. 1).
Moreover, mutant D23C9 also exhibited an enhanced
autolysis rate both in the phosphate buffer and lysis buffer
containing Triton X-100 (an inductor of autolysis), while a
reduced autolytic activity in the lysis buffer was observed in
D2P11 mutant (Fig. 2).
RTqPCR was performed to evaluate changes in the tran-
scription of pbp2 and pbp4 genes, involved in peptidoglycan
synthesis (Fig. 3A). The effect of subinhibitory concentrations
of vancomycin (1/4 MIC) on the transcription of these genes
was further analyzed. Transcription levels of the pbp2 and pbp4
genes were significantly different in the four strains ( p= 0.013
and p= 0.040 respectively, two-way ANOVA). A higher pbp2
expression was detected in strains D2, D23C9, and D2P11
when compared to strain D1 ( p< 0.05, Duncan post-test). This
observation correlates with PBPs pattern analysis (Fig. 3B). In
addition,mutantD23C9 showed a decreased pbp4 transcription
level when compared with the other strains ( p< 0.05, Duncan
post-test). Nevertheless, variations in transcription profile were
independent of the presence of subinhibitory concentrations of
vancomycin (1/4 MIC) ( p= 0.4026 and p= 0.3985, for pbp2
and pbp4, respectively, two-way ANOVA).
To further investigate genetic differences in candidate
loci involved in hVISA/VISA phenotype, the complete
vraTSR, walKR, and graXRS operons were amplified by
PCR and sequenced. No mutations were found in these
loci. In addition, the RRDR region of the rpoB gene was
analyzed. The four strains carried a mutation leading to the
FIG. 3. Expression of penicillin binding proteins. (A) Transcription levels of pbp2 and pbp4 genes by RTqPCR. Strains
named with ‘‘V’’ were incubated with VAN (¼ MIC). NRQ, normalized relative quantity. Bars represent the media and the
standard error of three determinations. A two-way analysis of variance was conducted to analyze the effect of two variables:
strain and vancomycin treatment. Expression levels of pbp2 and pbp4 genes were significantly different ( p = 0.0013 and
p = 0.040) and were not affected by vancomycin treatment ( p = 0.4026 and p = 0.3985, for pbp2 and pbp4, respectively).
Horizontal bars show the differences detected by Duncan post-test. (B) PBPs pattern by 10% SDS-PAGE (100mg of protein
in each lane). (1) Proteins incubated 30min at 37C with 25mM fluorescent ampicillin. (2) Proteins incubated 10min at
37C with 200mM ampicillin followed by 30min at 37C with 25 mM fluorescent ampicillin. PBPs were visualized as
described in Materials and Methods section. RTqPCR, reverse transcription quantitative real-time polymerase chain re-
action; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis.
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amino acid substitution H481N, which was previously re-
ported in clinical VISA strains.29
Discussion
HPLC-MS analysis of peptidoglycan muropeptides showed
an increased proportion of monomeric muropeptides and a
concomitant decrease in the proportion of tetrameric mur-
opeptide in D2 and derived mutants when compared to the
original strain D1. This fact has been described in hVISA and
VISA strains, where a decrease in the peptidoglycan cross-
linking degree has been shown.2 A much more pronounced
decreased cross-linking was observed inmutant D23C9, as per
the proportion of monomer muropeptides observed in the
HPLC chromatogram. This observation could be related to a
lower pbp4 gene transcription level observed by RTqPCR, and
is in agreement with the reduced cross-linking associated with
a loss of PBP4 previously reported in the strain MW2.30 In
addition, strain D2 and its derived mutants showed an increase
in cell wall thickness associated to an increased pbp2 gene
expression. The changes observed in the transcription profile of
pbp2 and pbp4 genes does not seem to be triggered by subin-
hibitory concentrations of vancomycin (1/4 MIC) as revealed
by RTqPCR.
In the light of these results, our findings point out that the
development of the VISA phenotype is related to a modi-
fication of peptidoglycan metabolism involving at least
PBP2 and PBP4, as described by other authors.2,15,19,31
It has been described that VISA phenotype might be
achieved by accumulation of differentmutations in other genes
related to cell wall metabolism.3 Unlike results reported by
other research groups, nomutations were found in the vraTSR,
graXRS, or walKR operons (related to cell wall synthesis and
homeostasis). Point mutations in several key genes that have
been shown to contribute to vancomycin resistance, or even
mutations in other loci implied in resistance to other antimi-
crobial families, could not be disregarded and perhaps explain
the changes in antibiotic susceptibility profile of D2, D23C9,
and D2P11.
Several authors have reported an increased resistance to
daptomycin together with a decrease in vancomycin suscep-
tibility.32–34 In this study, the VISA mutant D2P11 exhibited
a twofold increase in daptomycin MIC value compared to the
hVISA parental strain D2. This observation correlates with
the reduction in the inhibition zone of D2P11 compared to D2
in the prediffusion assay. Nevertheless, all the strains remain
daptomycin susceptible according to CLSI breakpoints.
It was described that vancomycin pressure (both in vitro
and in vivo) is associated with changes in rifampin resis-
tance.10,29 The VISA mutants described herein present a
reduction in rifampin MIC value when compared to the
hVISA clinical isolates D1 and D2 (rifampin resistant).
However, the rpoB sequence was the same across all iso-
lates. The mechanism by which rifampin resistance was
reduced in these strains is yet to be determined.
Different features have been described in association to
VISA strains such as reversion to a more susceptible pheno-
type, alteration in agr locus function, reduced autolysis rate,
and lower expression of PBP4 leading to the development of
reduced susceptibility to vancomycin.2,4 In this study, VISA
phenotype of the mutant D23C9 was stable, displayed en-
hanced autolysis rate, decreased pbp4 gene expression, and a
previously described loss of agr function14; on the other hand,
the D2P11 mutant, selected by an independent experiment,
showed a nonstableVISAphenotype, reduced autolysis rate (in
lysis buffer containing Triton X-100), and showed no changes
in pbp4 gene expression or agr function when compared to the
parental strain D2.
In Argentina, MRSA strains belonging to CC5 and CC30
are within the most prevalent lineages both in hospital and
community settings.35,36 It was described that some of the
changes reported in VISA strains might be related/linked to
specific MRSA genetic lineages.2 However, this study
shows that a single genetic background (CC5-ST100) under
vancomycin pressure could render VISA strains with dif-
ferential features and a comparable level of vancomycin
resistance. A similar observation was described by Vidaillac
et al. in laboratory mutants belonging to ST105 (which also
forms part of CC5).37 Therefore, it might be possible to
select different VISA phenotypes from the same genetic
background. This concept might explain the observed dif-
ferences in D23C9 and D2P11 mutants.
The factors implied in the development of hVISA/VISA
are probably diverse, and this perhaps might explain the di-
versity of mutations observed in strains reported from around
the world, whose phenotypes are comparable, but not com-
pletely identical. Since mutations in a heterogeneous popu-
lation (such as hVISA) might be randomly selected, different
pathways could lead to the VISA phenotype. The pleiotropic
effects of vancomycin selective pressure might lead to re-
duced susceptibility in association with changes in peptido-
glycan metabolism.
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